CF PHARMTECH (02652) Files with China Securities Regulatory Commission for Proposed H-Share Full Circulation

Stock News01-12

CF PHARMTECH (02652) announced that on January 12, 2026, the company submitted a filing application to the China Securities Regulatory Commission concerning the proposed implementation of an H-share full circulation. The plan involves converting approximately 107.4 million domestic non-traded shares into H-shares on a one-for-one basis. Upon completion of all filing requirements, including the filing with the CSRC, and after obtaining all relevant approvals—such as the Hong Kong Stock Exchange's approval for the conversion and listing—while complying with all applicable laws, regulations, and rules, the approximately 107.4 million non-traded shares will be converted into 107.4 million H-shares. These shares will subsequently be listed and traded on the Hong Kong Stock Exchange.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1178261156?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 21:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178261156","market":"us","top_or_hot":-1,"title":"CF PHARMTECH (02652) Files with China Securities Regulatory Commission for Proposed H-Share Full Circulation","media":"Stock News","content":"<p>CF PHARMTECH (02652) announced that on January 12, 2026, the company submitted a filing application to the China Securities Regulatory Commission concerning the proposed implementation of an H-share full circulation. The plan involves converting approximately 107.4 million domestic non-traded shares into H-shares on a one-for-one basis. Upon completion of all filing requirements, including the filing with the CSRC, and after obtaining all relevant approvals—such as the Hong Kong Stock Exchange's approval for the conversion and listing—while complying with all applicable laws, regulations, and rules, the approximately 107.4 million non-traded shares will be converted into 107.4 million H-shares. These shares will subsequently be listed and traded on the Hong Kong Stock Exchange.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CF PHARMTECH (02652) Files with China Securities Regulatory Commission for Proposed H-Share Full Circulation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCF PHARMTECH (02652) Files with China Securities Regulatory Commission for Proposed H-Share Full Circulation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-12 21:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CF PHARMTECH (02652) announced that on January 12, 2026, the company submitted a filing application to the China Securities Regulatory Commission concerning the proposed implementation of an H-share full circulation. The plan involves converting approximately 107.4 million domestic non-traded shares into H-shares on a one-for-one basis. Upon completion of all filing requirements, including the filing with the CSRC, and after obtaining all relevant approvals—such as the Hong Kong Stock Exchange's approval for the conversion and listing—while complying with all applicable laws, regulations, and rules, the approximately 107.4 million non-traded shares will be converted into 107.4 million H-shares. These shares will subsequently be listed and traded on the Hong Kong Stock Exchange.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02652","symbol_name":"长风药业","start_time":0,"source_url":"","article_id":"1178261156","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178261156","pubTimestamp":1768224499,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CF PHARMTECH (02652) announced that on January 12, 2026, the company submitted a filing application to the China Securities Regulatory Commission concerning the proposed implementation of an H-share...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02652":"长风药业"},"translate_title":"CF PHARMTECH(02652)向中国证监会提交建议H股全流通文件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02652":1},"content_text":"CF PHARMTECH (02652) announced that on January 12, 2026, the company submitted a filing application to the China Securities Regulatory Commission concerning the proposed implementation of an H-share full circulation. The plan involves converting approximately 107.4 million domestic non-traded shares into H-shares on a one-for-one basis. Upon completion of all filing requirements, including the filing with the CSRC, and after obtaining all relevant approvals—such as the Hong Kong Stock Exchange's approval for the conversion and listing—while complying with all applicable laws, regulations, and rules, the approximately 107.4 million non-traded shares will be converted into 107.4 million H-shares. These shares will subsequently be listed and traded on the Hong Kong Stock Exchange.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1178261156","isCrawlerRequest":true}